These results are also in line with an overall detection rate of 77 % in 4 clinical studies with 746 stage IV BRAF V600 mutant melanoma patients using BEAMing (beads, emulsions, amplification, and magnetics analysis) after cfDNA extraction from plasma [26–30]. The gene discussed is BRAF; the disease is melanoma.